You are here

A New Prostate Cancer Treatment to Improve Outcomes and Reduce Side-effects

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA210737-01
Agency Tracking Number: R41CA210737
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA15-270
Timeline
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-09-15
Award End Date (Contract End Date): 2018-08-31
Small Business Information
2500 CROSSPARK RD
Coralville, IA 52241-4710
United States
DUNS: 079244767
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 RYAN FLYNN
 (319) 384-8461
 ryan-flynn@uiowa.edu
Business Contact
 BLAKE DIRKSEN
Phone: (303) 968-7770
Email: blakedirksen@pxalpha.com
Research Institution
N/A
Abstract

PROJECT SUMMARY ABSTRACT Among men prostate cancer is the most common non skin cancer and
second leading cause of cancer death with over new diagnoses expected in Approximately
of men will be diagnosed with prostate cancer in their lifetime Current treatment options for prostate
cancer however have sub optimal incidences of side effects that have a significant impact on patientsandapos quality
of life including urinary incontinence and sexual dysfunction As prostate cancer patients may live with the side
effects of their treatment for decades there is a critical need for lower toxicity treatment techniques with an
equal or greater probability of cancer control than current techniques Here we propose a new prostate cancer
treatment technique Rotating Shield Brachytherapy RSBT RSBT uses a novel radiation source Gd
Unlike the Ir radiation source used in existing radiotherapy approaches Gd can be partially shielded
which enables the radiation source to emit a deliberately non symmetric dose distribution This effectively
directs radiation away from sensitive healthy tissues and into tumor tissue and therefore offers several
advantages over existing treatment techniques Our preliminary data indicate RSBT stands to become the
prostate cancer treatment with the lowest incidence of resulting sexual dysfunction gastro intestinal and
genitourinary toxicity due to its ability to reduce urethral rectal and bladder dose relative to conventional
treatments We hypothesize RSBT will further enable prostate cancer dose escalation beyond conventional
methods without increasing dose to healthy tissues thus improving metastasis free tumor control at years
post treatment RSBT may also reduce the number of treatment sessions patients need compared to current
therapies We have already developed concept models of several sub components of the prostate RSBT
system to prove each component can be successfully constructed for eventual integration into a full RSBT
prototype system Here we will demonstrate feasibility of the RSBT approach and its advantages over existing
treatments We will develop a prototype of the needle catheter source capable of delivering RSBT We will
develop RSBT apparatus functionality to enable the control and monitoring of the positioning of single catheter
with using a simple moving template design that converts translational template motion to rotational catheter
motion We will develop a multiple catheter control system by integrate the previously developed components
into a complete RSBT prototype and validate the complete system by dose measurement Successful
completion of these aims will demonstrate the feasibility and commercial potential of the RSBT approach
Ultimately this work will result in an improved clinically available prostate cancer treatment Our technology
stands to significantly reduce treatment related side effects for patients while providing equal or better cancer
control thus improving patientsandapos cancer outcomes and quality of life

http seer cancer gov statfacts html prost html
PROJECT NARRATIVE
Fourteen percent of all men will be diagnosed with prostate cancer in their lifetime and current prostate cancer
treatments have sub optimal incidences of side effects such as urinary incontinence and sexual dysfunction
As prostate cancer patients may live with these side effects for decades there is a critical need for lower
toxicity treatments We propose a new prostate cancer treatment technique with the potential to have the
lowest incidence of rectal urinary and sexual side effects while providing optimal cancer control

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government